Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Bahrain Pharmaceuticals and Healthcare Report Q4 2015

Bahrain Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: Bahrain's government will continue in its attempts at containing the rapidly expanding cost of
healthcare. Private sector engagement and increasing generic substitution will continue to be employed,
although government spending on the sector will continue to increase given its importance in social
stability. The uptake of compulsory health insurance and increased government spending will continue to
drive growth within the pharmaceutical market, with drugmakers viewing Bahrain as a small, but attractive
market.

$1,295.00
Botswana Pharmaceuticals and Healthcare Report Q4 2015

Botswana Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: Communicable diseases will continue to dominate Botswana's disease profile, with HIV/AIDS
posing the greatest burden. The government's provision of free antiretroviral treatment will provide
opportunities for generic drugmakers within the public healthcare sector. As the economy develops, the
burden of non-communicable diseases will increase, providing a more attractive epidemiological profile for
multinational drugmakers.
Headline Expenditure Projections

$1,295.00
Brazil Pharmaceuticals and Healthcare Report Q4 2015

Brazil Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: Continued focus on foreign investment along with the expansion of telemedicine and
governmental action to improve medical access will keep Brazil and appealing destination for drugmakers
and healthcare companies in coming years, particularly as the healthcare market remains an outperformer
in the country . This appeal, however, will remain limited in the short to medium term as Brazil's troubled
economy begins to negatively impact other industries including the healthcare and pharmaceutical industry

$1,295.00
Estonia Pharmaceuticals and Healthcare Report Q4 2015

Estonia Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: We expect growth in Estonia's healthcare expenditure to decelerate over the long term given the
country's fiscally conservative nature, the limited capacity of the national health insurer to accommodate
further healthcare spending growth and BMI's outlook for the country's economy over the long term.
Drugmakers can expect to see constrained revenue growth in the country as pricing pressures and restrictive
drug reimbursement will be employed by the Estonian health insurance fund to restrict healthcare
expenditure.

$1,295.00
Philippines Pharmaceuticals and Healthcare Report Q4 2015

Philippines Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: The proposed 2016 government budget will be positive for the Philippines healthcare sector.
The budget proposes a significant increase in funds allocated to the Department of Health which will
enable authorities to finance the expansion of the country's health insurance scheme and upgrade medical
facilities in the country. These two thrusts collectively address some of the key impediments to healthcare
access in the Philippines and will reinforce commercial opportunities for pharmaceutical companies

$1,295.00
Ukraine Pharmaceuticals and Healthcare Report Q4 2015

Ukraine Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: Ukraine's pharmaceutical market will continue to experience inflationary dynamics in 2015, as
the impact of the country's economic instability and the Ukrainian hryvnia's depreciation contribute to drug
price inflation. We expect market share will further shift towards domestic pharmaceutical companies as
the price of imported medicines makes them increasingly unaffordable to consumers. As a result, Ukraine's
attractiveness to multinational drugmakers will decline significantly in the short-term.

$1,295.00
United Kingdom Pharmaceuticals and Healthcare Report Q4 2015

United Kingdom Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Sep 2 2015

BMI View: As a global major powerhouse in R&D and manufacturing of medicines and biotechnology, the
UK will continue to present room for strong sector development, which will be further supported by the last
financial year increase of foreign direct investment in the UK as well as a sustained economic growth
trajectory. This is illustrated by an uptick in multinational funding and venture capital deals in the biotech
industry, such as Inmunocore's latest successful private financing round, investments in the life sciences

$1,295.00
Maternity and Child Care (MCC) Hospitals Market in India 2015 - 2020

Maternity and Child Care (MCC) Hospitals Market in India 2015 - 2020

Date Published: Aug 27 2015
Indian maternity and child care (MCC) hospitals market is expected to grow at a CAGR of 38% by 2020, finds a new research report launched by NOVONOUS.
$2,500.00
Myanmar Pharmaceuticals and Healthcare Report Q4 2015

Myanmar Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
Out-of-pocket payments will remain a key source of healthcare financing in Myanmar over the medium term. Central to this view will be the slow uptake of private health insurance as the sub-sector remains new to the country and has a premium structure that is largely unaffordable to the majority of the population. Furthermore, coverage is limited, which will see out-of-pocket payments accounting for the majority of hospitalisation fees.
 

Headline Expenditure Projections 

$1,295.00
Peru Pharmaceuticals and Healthcare Report Q4 2015

Peru Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
Longstanding trade agreements, a growing dependence on foreign pharmaceuticals and the expansion of a national telemedicine network will continue to improve Peru's appeal to foreign investors in coming years. A rising burden of chronic conditions driving a growing medicine demand will keep healthcare spending on a positive trajectory in the country, assisted by Peru's positive economic outlook for 2015.
 

Headline Expenditure Projections 

$1,295.00
Sri Lanka Pharmaceuticals and Healthcare Report Q4 2015

Sri Lanka Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
The fragmented nature of the Asia Pacific region will continue to provide unequal commercial opportunities for pharmaceutical firms looking to invest in the region. Sri Lanka's pharmaceutical sector managed to attract investments from both domestic and foreign investors in recent years, as economic growth has picked up and the government remains focused on improving the domestic pharmaceutical sector. We expect that pharmaceutical and healthcare sector growth will outpace economic growth over the five-year forecast period.
 
$1,295.00
Sweden Pharmaceuticals and Healthcare Report Q4 2015

Sweden Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015

BMI View: Declining government reimbursement for prescription medicines and the promotion of lowervalue
generic medicines does not bode well for innovative drugmakers selling their products in Western
Europe, particularly as governments are the primary purchasers of pharmaceuticals. Furthermore, over the
long-term, pushing costs onto a population with fewer young people to financially support the elderly will
ultimately work to reduce the consumption of higher-value innovative pharmaceuticals.
Headline Expenditure Projections

$1,295.00
Taiwan Pharmaceuticals and Healthcare Report Q4 2015

Taiwan Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015

BMI View: Taiwan will remain a key destination for clinical trials due to the government's efforts to
augment the country's medical infrastructure and streamline clinical research regulatory processes. In
addition, there will be further upsides to the clinical trials sector should Taiwan be able to successfully
harmonise its regulations with China and allow for the mutual recognition of data.
Headline Expenditure Projections
■ Pharmaceuticals: TWD167.7bn (USD5.5bn) in 2014 to TWD175.1bn (USD5.6bn) in 2015; +4.4% in

$1,295.00
Bulgaria Pharmaceuticals and Healthcare Report Q4 2015

Bulgaria Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
Strong pharmaceutical sales growth in 2015 will be moderated over the medium term by cost containment measures. Healthcare payers in Central and Eastern Europe will become increasingly assertive in using their purchasing power to demand discounts from drugmakers in order to contain rising healthcare costs. The announcement of a joint procurement drive with Romania will increase pricing pressures on pharmaceutical manufacturers over the long term.
 

Headline Expenditure Projections 

$1,295.00
Uganda Pharmaceuticals and Healthcare Report Q4 2015

Uganda Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015

BMI View: Uganda's pharmaceutical market remains dampened by poor funding and consequently
underdevelopment. The private sector makes up the clear majority of pharmaceutical spending in the
country in terms of value and strong private consumption growth will drive medicine spending further in
this regard. Opportunities will be present for those multinationals involved in the selling of high-value
patented drugs. A growing communicable and non-communicable disease burden will also contribute to

$1,295.00
Canada Pharmaceuticals and Healthcare Report Q4 2015

Canada Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
$1,295.00
Germany Pharmaceuticals and Healthcare Report Q4 2015

Germany Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
As the German economy observes signs of a tentative long-term rebalancing in which private consumption will play a more significant role in economic growth, recent improvements in high frequency indicators have lead us to an upward revision of the pharmaceutical market growth forecast for 2015.
 
$1,295.00
Jordan Pharmaceuticals and Healthcare Report Q4 2015

Jordan Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
The majority of Jordan's pharmaceuticals will remain sourced from abroad despite the impressive domestic manufacturing industry. Local drugmakers will continue to supply the market with generic medicines but higher value innovative drugs will continue to be supplied by multinationals. Significant counterfeit medicine circulation and economic and political instability in neighbouring Syria will weigh down the domestic pharmaceutical markets appeal to foreign investment.
 
$1,295.00
Kazakhstan Pharmaceuticals and Healthcare Report Q4 2015

Kazakhstan Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
$1,295.00
Kuwait Pharmaceuticals and Healthcare Report Q4 2015

Kuwait Pharmaceuticals and Healthcare Report Q4 2015

Date Published: Aug 26 2015
Kuwait's pharmaceutical sector will remain dominated by multinational drugmakers given the preference for branded products among both prescribers and consumers. Development of the local generics sector will be stimulated by the implementation of cost-containment measures within the healthcare sector.
 

Headline Expenditure Projections 

$1,295.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data